Purpose: Cancer diagnostics and therapeutics are often based on clinically relevant markers that are expressed specifically in a malignant tissue at levels higher than in normal tissue. We examined potential markers for papillary thyroid carcinoma (PTC) by monitoring PTC-specific gene expression using cDNA microarray.
INTRODUCTION
Papillary thyroid carcinoma (PTC) is the most common malignant thyroid tumor, representing 80 -90% of all thyroid malignancies. Papillary, follicular, and anaplastic thyroid carcinomas arise from follicular cells; medullary thyroid carcinomas arise from the parafollicular epithelium of the thyroid. PTC is usually well differentiated; however, the clinical behavior of PTC varies widely. For example, incidental microcarcinomas grow very slowly and are noninvasive or minimally invasive. On the other hand, invasive PTC with metastasis can be lethal. PTC often recurs many years after surgical removal. The prognosis for PTC is often favorable; however, ϳ20% of PTC tumors recur (1) , and some reach advanced stages. Postoperative follow-up for diagnosing recurrence is important for a favorable outcome. Although PTC can be diagnosed by fine-needle aspiration cytology, this method is not sufficiently reliable for predicting postoperative clinical outcome. Serum thyroglobulin (TG) has been monitored by immunoassay to detect the recurrence of differentiated thyroid carcinoma. However, measurement of serum TG is sometimes hindered by the presence of circulating factors, particularly anti-TG antibodies (2) , and residual normal thyroid (NT) gland tissue that produces TG. Thus, a reliable diagnostic molecular marker for PTC would be extremely valuable for improving cancer detection and the prognosis of patients with PTC.
A common approach for identifying circulating cancer cells in peripheral blood is the reverse transcription-PCR (RT-PCR) method for amplifying tumor-specific mRNA (3, 4) . Another possible approach is to measure abnormal or ectopic tissue-specific gene expression in peripheral blood. Previous studies have investigated the thyroid-specific markers TG, thyroid peroxidase (TPO), Ret/PTC1, and human sodium/iodide symporter (NIS) as diagnostic markers of thyroid carcinomas (5) (6) (7) (8) . However, expression of TG is reportedly not thyroid specific and is not correlated with thyroid cancer (9, 10) . Although RT-PCR detection of a marker for circulating cancer cells in peripheral blood would be an effective noninvasive method, a reliable marker for PTC has not yet been identified.
Use of a cDNA microarray is a powerful method for the quantitative analysis of cancer-specific gene expression (11, 12) that can detect altered gene expression associated with the pathology or the altered biology of cancer cells. A cDNA microarray can be used to identify potential diagnostic markers for cancer by measuring tumor-specific expression of thousands of genes in hundreds of tumors. Candidate genes for diagnostic markers can also be characterized by analyzing the gene expression profiles of a small number of cancer tissues in combination with the further large-scale immunohistochemical analysis of protein expression.
In this study we examined potential PTC-specific molecu- 
MATERIALS AND METHODS
Tissue and RNA Extraction. Thyroid tissue was obtained from patients undergoing surgery for thyroid disease at University Hospital, University of Tsukuba (Tsukuba, Japan). Tissues were immediately frozen in liquid nitrogen and stored at Ϫ80°C until use. The protocol was approved by the Institutional Review Board, and informed consent was obtained. Seven highly differentiated papillary carcinomas were chosen for microarray studies. Paired samples of normal and tumoral thyroid tissues from the same patients were studied. Histologically verified NT tissues were obtained from four patients undergoing thyroidectomy for a solitary benign thyroid neoplasm. Peripheral blood cells (PBCs) were obtained from whole blood of healthy volunteers. Total RNA was obtained with a commercial kit (ISOGEN; Nippon Gene, Tokyo, Japan) according to manufacturer's protocol. The RNA quality was confirmed by subjecting the sample to electrophoresis on a formaldehyde-agarose gel and staining the 18S and 28S RNA bands for visualization.
Microarray Preparation. A 5-l aliquot of sequenceverified human 3968 cDNA (Invitrogen, Carlsbad, CA) was added to 2.5 ml of Terrific broth (Difco, Detroit, MI) containing ampicillin and incubated at 37°C overnight. Plasmid DNA was extracted from each culture in a 96-well format by use of an alkaline-SDS method with a MultiScreen plate (Millipore, Bedford, MA). The microarray membrane was prepared with human 3968 cDNA, which contains genes named in the UniGene database (National Center for Biotechnology Information, Bethesda, MD). The cDNA insert was diluted and amplified by standard PCR protocols using the primer set GF-FW (5Ј-CTG CAA GGC GAT TAA GTT GGG TAA C-3Ј) and GF-RV (5Ј-GTG AGC GGA TAA CAA TTT CAC ACA GGA AAC AGC-3Ј). The amplification products, including thyroid-specific cDNAs, were purified by use of Multi Screen-PCR plates (Millipore) and spotted on Hybond-N Plus membranes (Amersham, Buckinghamshire, United Kingdom) with a GTMASS arrayer (NLE, Nagoya, Japan).
Hybridization and Data Analysis. A 2-g portion of total RNA was dissolved in 8 l of RNase-free water; 2 l of oligo(dT) primer (1 g/l; Invitrogen) were then added. The sample was heated for 10 min at 70°C and immediately chilled on ice. The following were then added to the sample: 5 l of first-strand cDNA synthesis buffer, 1 l of DTT (0.1 M final concentration), 1.5 l of deoxynucleotide triphosphates (20 mM dATP, dGTP, and dTTP), 1.5 l of SuperScript (200 units/l; Invitrogen), and [␣- 33 P]dCTP (3000 Ci/mmol; Amersham). The reaction was incubated at 37°C for 90 min. Labeled cDNA was then purified by use of Bio-Spin 6 chromatography columns (Bio-Rad Laboratories, Hercules, CA) and denatured for 3 min at 95°C. The microarray was prehybridized at 42°C for 2 h in MicroHyb solution (Invitrogen) with 0.5 g/ml poly(dA) and 1 g/ml COT1 DNA (Invitrogen). The probes were hybridized at 42°C overnight in the same solution. The membrane microarray was washed twice at 50°C with 2ϫ SSC-1% SDS for 20 min and at room temperature with 0.5ϫ SSC-1% SDS for 15 min. The membrane microarray was exposed to an imaging plate, which was scanned with a BAS 5000 imaging analyzer (Fuji Film, Tokyo, Japan). Spot intensity was quantified with ArrayVision 5.0 software (Imaging Research, Ontario, Canada). GeneSpring 5.0 software (Silicon Genetics, Redwood, CA) was used to normalize values for each gene and each microarray, and for data analysis.
The accuracy of microarray data was determined by six repeat analyses of the same RNA from NT tissue. Probes were stripped by boiling with 0.5% SDS before rehybridization.
Northern Blot Analysis. Aliquots containing 10 g of total RNA were electrophoresed on a 1% formaldehyde-agarose gel, transferred to a nylon membrane, and immobilized by baking the filters at 80°C for 2 h. The membrane was prehybridized with Church's solution (0.5 M sodium phosphate-7% SDS-1 mM EDTA) at 68°C for 2 h. The DNA fragments for adrenergic receptor ␤ kinase 1, myeloid leukemia factor, TG, TPO, thyroid-stimulating hormone receptor (TSHR), and glyceraldehyde-3-phosphate dehydrogenase were amplified from cDNA and sequenced by a standard protocol. After sequence confirmation, the DNA fragment was labeled with [␣-32 P]dCTP by a random primer cDNA labeling method with the commercial Megaprime DNA Labeling System (Amersham). The heatdenatured probe was added to the prehybridization solution and incubated at 68°C overnight.
Real-Time Quantitative PCR for Determination of mRNA Levels. The gene expression levels of NIS, TPO, and the Ret proto-oncogene (RET) were examined by real-time quantitative PCR. A 1-g aliquot of total RNA for each sample was reverse-transcribed in a 100-l reaction volume with a commercial High-Capacity cDNA Archive Kit (Applied Bio- systems PE) according to manufacturer's protocol. The quantitative PCR reaction was carried out in 96-well microtiter plates on the ABI Prism Sequence Detector 7900 (Applied Biosystems) with a commercial Assays-on-Demand kit (Applied Biosystems). The probe sequences for PCR were as follows: 5Ј-GGC GCT CTG CAC CAG ATC ATC ACC C-3Ј for TPO; 5Ј-GGC TCC TGG GAG GGT GAG GGT CTG CC-3Ј for RET; and 5Ј-AGC TGC CTG ACA GGC CCC ACC AAG C-3Ј for NIS. For each sample of each gene, PCR amplification was performed in triplicate with 18S rRNA used as an endogenous control. The mRNA content of each target was determined simultaneously in three paired normal/tumoral samples studied by DNA array analysis.
Immunohistochemistry. Archival formaldehyde-fixed, paraffin-embedded blocks were obtained from Tsukuba University Hospital. Sections were cut 5-m thick, deparaffinized, and rehydrated. Antigen retrieval for platelet-derived growth factor (PDGF) antibody staining was performed with 0.01 M citrate buffer. Endogenous peroxidase activity was inactivated with a blocking agent. After washing, the sections were exposed to a 1:100 solution of antihuman basic fibroblast growth factor (bFGF) monoclonal antibody (WAKO Pure Chemical Industries, Osaka, Japan) or PDGF polyclonal antibody (WAKO Pure Chemical Industries) at 4°C overnight and incubated with peroxidase-labeled dextran polymer (Envision Plus System; DAKO, Kyoto, Japan) for 1 h. Staining without primary antibodies was used as a negative control. For visualization, tissue sections were soaked in medium containing 3,3-diaminobenzidine tetrahydrochloride and H 2 O 2 and were counterstained with hematoxylin. Cytoplasmic staining was assessed by identifying and scoring 100 cells within a randomly selected light microscopic field (ϫ400 magnification). The cytoplasm of those cells was scored as 0 (no staining), 1 (mild staining), 2 (moderate staining), or 3 (heavy staining) by two independent observers. The results are presented as proportions of 1000 cells (fields from multiple slides were examined) from which the histochemical score for determining the level of expression was then calculated (13) . Expression was considered to be positive when the histochemical score was Ͼ75.
Cytological specimens were obtained intraoperatively by fine-needle aspiration. Cells were smeared on the slide and fixed in formaldehyde. The PDGF protein expression was examined as described above. 
RESULTS
Microarray Quality Control. We estimated the reproducibility and accuracy of the microarray data by carrying out six repeat experiments using the 3968 cDNA microarray and a NT cDNA probe. Data were collected for the same probe hybridized to four membranes, two of which were then stripped and rehybridized, generating six data sets (data not shown). The same membranes were used in experiments 1 and 5 and in experiments 2 and 6. The average normalized spot intensity for each data set was 1.0, and the SD was 0.7.
Hierarchical Clustering Analysis. Expression profiles were analyzed for seven PTC samples and seven NT samples, including three pairs of normal/tumoral thyroid tissues. The cutoff for differential expression associated with PTC was set at 2.0-fold. Clustering analysis was performed with the modelbased approach with GeneSpring software and showed a similar expression pattern among PTC samples (Fig. 1) . Most of the NT tissue samples were clustered in one group, and the tumors were clustered in another group. The NT and PTC groups were separated by the differential expression of genes; these differences were determined to be statistically significant by the t test (Ͻ0.05). Several genes showed up-regulated expression patterns in PTC (Table 1 ). The proteins encoded by the altered genes are associated with cell cycle regulators, growth regulators, oncogenes, and DNA damage regulators.
Corroboration of Gene Expression. Northern blot analysis was used to confirm the results of the microarray studies. Northern blots were prepared with the samples used in the microarray study plus one follicular carcinoma sample and two follicular adenoma samples (Fig. 2A) . The blots were hybridized with probes for ␤-adrenergic receptor kinase 1, myeloid leukemia factor, and TG. The results confirmed microarray data showing that these genes are up-regulated in PTC (Fig. 2B) . Expression of TPO was down-regulated in PTC and follicular carcinoma samples. The gene TSHR was expressed at a lower level in two of the PTC samples than in the NT samples. The mRNA for TPO, TSHR, and TG was not detected in PBCs.
We analyzed the differential expression of three genes related with thyroid disease in five paired normal/tumoral thyroid tissue samples by quantitative PCR. The levels of expression determined by RT-PCR correlated with the results obtained by microarray analysis (data not shown). Wild-type RET showed a minute amount of mRNA in both normal and welldifferentiated PTC tissues. PTC-Specific Gene Expression. Genes that were differentially expressed in PTC compared with paired normal tissue obtained from the same patients were also detected. We focused on those genes that showed up-regulated expression in at least one NT/PTC pair and statistically different expression from other NT samples. This screening identified 64 genes showing a Ͼ2-fold increase in expression. Table 2 summarizes the tumor-related genes that showed PTC-specific expression (PTC/NT ratio).
TG, PDGF, and FGF expression levels are shown in Fig.  3A . The TG expression pattern was predominant in PTC samples; however, its up-regulated signal was also seen in healthy Fig. 4 Overexpression of basic fibroblast growth factor (bFGF) in papillary thyroid carcinoma. Thyroid tissues are stained with anti-bFGF antibody. Immunopositivity is visualized as a brown stain, whereas nuclear staining is blue. bFGF staining is localized primarily in tumor cells with weak staining for stroma (A). Positive bFGF staining is localized in the cytoplasm in cases of papillary thyroid carcinoma (B and C). Hyperfunctioning thyroid tissue (D) and thyroid follicular adenoma (E) showed weak immunopositive staining. No staining was observed in the normal follicular cell sample (F). Original magnifications are, as follows: A, ϫ100; B-F, ϫ400.
PBCs. On the other hand, PDGF and FGF expression was low in PBCs. We compared expression of the thyroid-specific genes TG, TPO, TSHR, and NIS and of RET between paired PTC and NT samples (Fig. 3B) . TG was up-regulated in PTC samples, whereas the levels of TPO, RET, and NIS were reduced. The expression of TSHR was down-regulated in two PTC samples.
PTC-Specific Protein Expression. Because bFGF and PDGF were identified as potential diagnostic tools for PTC from their gene expression, their protein expression was also examined in thyroid tissues. Protein expression was examined by immunohistochemical analysis of 91 thyroid tissue sections [55 differentiated PTCs, 4 follicular variant PTCs, 6 follicular thyroid carcinomas, 5 hyperfunctioning thyroid tissues, 11 benign thyroid neoplasms, and 10 NT samples]; these samples included the tissues analyzed by microarray. The results of the immunohistochemical analysis are summarized in Table 3 . Thirty-four of 59 (54%) PTCs were positive for bFGF, but none of the 10 NT samples were positive. Positive staining for bFGF was also observed in hyperfunctioning thyroid tissues and benign neoplasms (Fig. 4) . Thyroid PTC and follicular thyroid carcinoma neoplasms showed increased proportions of positive immunostaining for PDGF: 48 of 59 (81%) cases of PTC and 6 of 6 (100%) cases of follicular thyroid carcinoma. On the other hand, follicular cells in NT tissue from a multinodular goiter and an adenoma were negative for PDGF immunostaining. As shown in Fig. 5 , immunochemical analysis showed that neoplastic cells retrieved by fine-needle aspiration biopsy were immunoreactive for PDGF.
DISCUSSION
In this study microarray analysis showed that the genes bFGF and PDGF were overexpressed in PTC. This result confirms previous reports that the bFGF protein is detected in PTCs (14, 15) ; however, studies of bFGF or PDGF at the mRNA level or of PDGF at the protein level have not been done. The bFGF isolated from PTC samples was reported to be similar to bFGF from other sources and was reported to play an important role in the angiogenesis and proliferation of parenchymal cells (16) . In this study, we found that PDGF was a potential diagnostic marker of PTC. The expression of PDGF was detected in PTCs but not in normal tissues by immunohistochemical staining. The bFGF antibody displayed increased protein levels in malignant neoplasms as well as in benign thyroid diseases. On the other hand, PDGF showed a high frequency of positive staining in cases of thyroid malignancy (81% of PTCs), and its expression was specifically detected in malignant but not benign thyroid diseases. These results showed that PDGF is a potential diagnostic marker. Fujimoto et al. (17) previously suggested that serum bFGF could be used as a highly specific diagnostic marker for renal cell carcinoma. Similarly, serum PDGF might be used as a diagnostic marker for PTC, and this possibility is under investigation.
Cytological specimens from fine-needle aspirates were also immunoreactive for PDGF. Physicians make their diagnosis of PTC on the basis of morphology from fine-needle aspirate biopsy samples, but not immunochemistry. Immunostaining these samples for PDGF may be helpful for identifying PTC. On the basis of our results for fine-needle aspirate cytology, thyroid tumors could be more accurately diagnosed by a combination of morphological diagnosis and detection of PDGF expression.
Microarray analysis was performed on 4000 human cDNA arrays and RNA from 7 PTC samples and 7 normal samples, including 3 PTC/NT pairs. The reproducibility of the microarray data was confirmed. Clustering analysis classified samples as PTC or NT and identified 64 genes whose expression is upregulated in PTC but low or undetectable in NT and PBCs. Although more clinical cases need to be studied, the expression profiles of selected genes in these PTC samples may be representative of this type of cancer cell.
Of the 64 genes with up-regulated expression, several genes may be candidates as diagnostic markers for thyroid carcinoma. Such markers could be particularly useful for monitoring patients postoperatively. An ideal biomarker for cancer in its early diagnosis should have both tumor and tissue specificity. Our microarray screening did not give any information about tissue specificity. Although a protein that shows both tumor and tissue specificities might be rare, a detailed study of the candidate genes detected by the microarray in this study might successfully find such biomarkers.
Previous studies have similarly identified genes up-regulated in PTC [i.e., fibronectin 1 (18), galectin-3 (19), S100 calcium-binding proteins (20, 21) , and insulin receptor (22) ], indicating that these genes may be involved in the development of thyroid carcinogenesis. From previous microarray studies (23, 24) , it is difficult to identify common up-regulated genes in PTC. Overlapping gene expression among microarray studies may depend on the microarray probe design, which may explain some of the overlap between studies. However, several of the genes related to cell cycle, carcinogenesis, oncogene, and growth factors showed similar expression patterns in our and other studies.
The thyroid follicular cell is a highly differentiated cell that responds to thyroid-stimulating hormone, traps iodine, and synthesizes TG and TPO. Thus, TG, TPO, and TSHR can be used as markers for the differentiation of follicular cells. In this study, TG was expressed at a high level in PTC. However variable levels of TG expression have been observed in thyroid malignancies (25) (26) (27) (28) (29) (30) . Some studies reported that the expression was not thyroid specific (9, 10) ; in fact, we found TG expression in healthy PBCs. We selected three thyroid-related genes for additional analysis to validate the microarray expression data. In this study, we found that the gene expression levels of TPO and NIS were decreased; this supports previous findings (28, 30 -32) . The gene RET, a tyrosine kinase receptor, may be a major proto-oncogene in thyroid carcinogenesis: RET rearrangement is the most common genetic alternation found in PTC (33) (34) (35) . In this study we did not detect RET gene expression in NT tissue and found different levels of expression in PTC samples. These data coincide with previous reports using RT-PCR (36) .
In summary, this study demonstrates that microarray technology can be used to develop molecular markers for cancer diagnosis. Some of the genes shown to have strong expression might be used as serum tumor markers of thyroid cancers. In particular, gene expression profiling was used to identify genes differentially regulated in PTC. From this set of genes, PDGF was identified as a strong candidate diagnostic marker for PTC because it was highly expressed in 81% of PTC cases at the protein level. Antibodies to PDGF could be extremely useful in future studies to evaluate the clinical potential of PDGF as a diagnostic marker for PTC. The expression profiling data presented here may also improve our understanding of thyroid carcinogenesis.
